Case Report: Malignant Melanoma Treated with Ipilimumab and Nivolumab in Patient with Multiple Sclerosis
DOI:
https://doi.org/10.14738/bjhr.1202.18696Keywords:
malignant melanoma, multiple sclerosis, immunotherapy, checkpoint inhibitors, ipilimumab, nivolumabAbstract
This case report presents a patient with relapsing and remitting multiple sclerosis (MS) and metastatic malignant melanoma treated with combination immunotherapy. Ipilimumab and nivolumab was tolerated with no significant adverse events. There was no progression of multiple sclerosis while she received immunotherapy. This demonstrates that Ipilimumab and nivolimumab can be considered in patients with pre-existing multiple sclerosis requiring treatment with checkpoint inhibitors, but should have close multidisciplinary monitoring.
References
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.02229.
Hodi, F Stephen et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology, Volume 17, Issue 11, 1558 – 1568. Doi: 10.1016/S1470-2045(16)30366-7.
Brown LJ, Weppler A, Bhave P, et al. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer. 2021;9(5): e002121. doi:10.1136/jitc-2020-002121. 400 Abbas, T. & Sundaram, V. (2025). Case Report: Malignant Melanoma treated with Ipilimumab and Nivolumab in Patient with Multiple Sclerosis. British Journal of Healthcare and Medical Research, Vol - 12(02). 398-401.
Reid P, Abdel-Wahab N. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology. 2023;12(1):e2205861 .
Quinn CM, Kister I. Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications. Neurology. 2024;103(11): e210003. doi:10.1212/WNL.0000000000210003.
van der Kooij MK, Kapiteijn E. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease. Ann Intern Med. 2021;174(5):641-648. DOI.10.7326/m20-3419
Dumbrava EE, Dougan ML, Gupta S, et al. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). J Clin Oncol. 2021;39(15_suppl): TPS2676-TPS2676. doi: 10.1200/JCO.2021.39.15 suppl. TPS2676
Public Health Agency of Canada, “Multiple sclerosis in Canada,” Canada.ca, May 29, 2024. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/ multiple-sclerosisinfographic.html.
Menzies AM, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016;27(4):724-730.
Das N, Reddy D. Adverse neurologic complications following immune checkpoint inhibitors for treatment of melanoma: Comparative analysis of PD-1 inhibitor monotherapy to combination therapy with CTLA-4 inhibitors. Neuro-Oncol. 2024;26(8-suppl)218. doi.10.1093/neuonc/noae165.0860
Schmidt T, Glas M. Pseudomeningeosis and demyelinating metastasis-like lesions from checkpoint inhibitor therapy in malignant melanoma. Front Oncol.2021; 11:754253. doi; 10.3389/fonc.2021.637185
Mancone S, Strowd R. Neurological complications of immune checkpoint inhibitors: a case series (P4.159).J Neurol. 2018;265(7):1636-1642. Doi:10.1007/800415-081-8890-z
Yan C, McGinley MP. Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality. EurJNeurol.2023;30(10):3321-3327. Doi.10.1111/ene.15942.
Vaddepally R, Kumar N. Case Report: A case of immune checkpoint inhibitor therapy in a patient with multiple sclerosis. F1000Research. 2020; 9:954.
Garcia CR, Jayswal R, Adams V et al. Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl oncol. 2019;21910):1336-1342. Doi:10.1007/s12094-019-02060-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Tahir Abbas, Vinita Sundaram
This work is licensed under a Creative Commons Attribution 4.0 International License.
